New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin (Q35086080)

6 August 2017

1 reference

title

New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin (English)

1 reference

6 August 2017

0 references

1

Andrew V Schally

1 reference

6 August 2017

Attila Nagy

2

1 reference

PubMed ID

12639697

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

6 August 2017

1 reference

6 August 2017

72

1 reference

6 August 2017

21

1 reference

6 August 2017

2305-2320

1 reference

Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Potent bombesin antagonists with C-terminal Leu-psi(CH2-N)-Tac-NH2 or its derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Synthesis and biological activity of highly potent octapeptide analogs of somatostatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Human ovarian cancers express somatostatin receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Targeted cytotoxic analogue of luteinizing hormone-releasing hormone (LH-RH) only transiently decreases the gene expression of pituitary receptors for LH-RH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Molecular pharmacology of somatostatin receptor subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Hypothalamic hormones and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Peptide analogs in the therapy of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900113-9

10.1016/S0024-3205(03)00113-9

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12639697